Selected research
Industry Research
Biopharmaceutical CRO Industry Research Report 2026
Market perspective
The global Biopharmaceutical CRO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Biopharmaceutical CRO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Biopharmaceutical CRO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Biopharmaceutical CRO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Biopharmaceutical CRO include WuXi AppTec, WuXi Biologics, Hangzhou Tigermed, Pharmaron Beijing, ICON, PPD, BioPharma Services, TriStar Technology Group and Fortrea, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Biopharmaceutical CRO market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Biopharmaceutical CRO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biopharmaceutical CRO Market by Company
WuXi AppTec
WuXi Biologics
Hangzhou Tigermed
Pharmaron Beijing
ICON
PPD
BioPharma Services
TriStar Technology Group
Fortrea
Eurofins BioPharma Services
Medicilon
Asymchem
UBC
SanaClis
TFS HealthScience
Parexel
Biopharmaceutical CRO Segment by Type
Full-service CRO
Specialized CRO
Biopharmaceutical CRO Segment by Application
SMBs
Large Enterprises
Biopharmaceutical CRO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biopharmaceutical CRO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biopharmaceutical CRO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biopharmaceutical CRO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Biopharmaceutical CRO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Full-service CRO
- Specialized CRO
Applications
- SMBs
- Large Enterprises
Companies covered
- WuXi AppTec
- WuXi Biologics
- Hangzhou Tigermed
- Pharmaron Beijing
- ICON
- PPD
- BioPharma Services
- TriStar Technology Group
- Fortrea
- Eurofins BioPharma Services
- Medicilon
- Asymchem
- UBC
- SanaClis
- TFS HealthScience
- Parexel
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Biopharmaceutical CRO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Full-service CRO
- 2.2.3 Specialized CRO
- 2.3 Biopharmaceutical CRO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 SMBs
- 2.3.3 Large Enterprises
- 2.4 Assumptions and Limitations
3 Biopharmaceutical CRO Breakdown Data by Type
- 3.1 Global Biopharmaceutical CRO Historic Market Size by Type (2021-2026)
- 3.2 Global Biopharmaceutical CRO Forecasted Market Size by Type (2027-2032)
4 Biopharmaceutical CRO Breakdown Data by Application
- 4.1 Global Biopharmaceutical CRO Historic Market Size by Application (2021-2026)
- 4.2 Global Biopharmaceutical CRO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Biopharmaceutical CRO Market Perspective (2021-2032)
- 5.2 Global Biopharmaceutical CRO Growth Trends by Region
- 5.2.1 Global Biopharmaceutical CRO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Biopharmaceutical CRO Historic Market Size by Region (2021-2026)
- 5.2.3 Biopharmaceutical CRO Forecasted Market Size by Region (2027-2032)
- 5.3 Biopharmaceutical CRO Market Dynamics
- 5.3.1 Biopharmaceutical CRO Industry Trends
- 5.3.2 Biopharmaceutical CRO Market Drivers
- 5.3.3 Biopharmaceutical CRO Market Challenges
- 5.3.4 Biopharmaceutical CRO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Biopharmaceutical CRO Players by Revenue
- 6.1.1 Global Top Biopharmaceutical CRO Players by Revenue (2021-2026)
- 6.1.2 Global Biopharmaceutical CRO Revenue Market Share by Players (2021-2026)
- 6.2 Global Biopharmaceutical CRO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Biopharmaceutical CRO Head Office and Area Served
- 6.4 Global Biopharmaceutical CRO Players, Product Type & Application
- 6.5 Global Biopharmaceutical CRO Manufacturers Established Date
- 6.6 Global Biopharmaceutical CRO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Biopharmaceutical CRO Market Size (2021-2032)
- 7.2 North America Biopharmaceutical CRO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Biopharmaceutical CRO Market Size by Country (2021-2026)
- 7.4 North America Biopharmaceutical CRO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Biopharmaceutical CRO Market Size (2021-2032)
- 8.2 Europe Biopharmaceutical CRO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Biopharmaceutical CRO Market Size by Country (2021-2026)
- 8.4 Europe Biopharmaceutical CRO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Biopharmaceutical CRO Market Size (2021-2032)
- 9.2 Asia-Pacific Biopharmaceutical CRO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Biopharmaceutical CRO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Biopharmaceutical CRO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Biopharmaceutical CRO Market Size (2021-2032)
- 10.2 South America Biopharmaceutical CRO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Biopharmaceutical CRO Market Size by Country (2021-2026)
- 10.4 South America Biopharmaceutical CRO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Biopharmaceutical CRO Market Size (2021-2032)
- 11.2 Middle East & Africa Biopharmaceutical CRO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Biopharmaceutical CRO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Biopharmaceutical CRO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 WuXi AppTec
- 12.1.1 WuXi AppTec Company Information
- 12.1.2 WuXi AppTec Business Overview
- 12.1.3 WuXi AppTec Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.1.4 WuXi AppTec Biopharmaceutical CRO Product Portfolio
- 12.1.5 WuXi AppTec Recent Developments
- 12.2 WuXi Biologics
- 12.2.1 WuXi Biologics Company Information
- 12.2.2 WuXi Biologics Business Overview
- 12.2.3 WuXi Biologics Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.2.4 WuXi Biologics Biopharmaceutical CRO Product Portfolio
- 12.2.5 WuXi Biologics Recent Developments
- 12.3 Hangzhou Tigermed
- 12.3.1 Hangzhou Tigermed Company Information
- 12.3.2 Hangzhou Tigermed Business Overview
- 12.3.3 Hangzhou Tigermed Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.3.4 Hangzhou Tigermed Biopharmaceutical CRO Product Portfolio
- 12.3.5 Hangzhou Tigermed Recent Developments
- 12.4 Pharmaron Beijing
- 12.4.1 Pharmaron Beijing Company Information
- 12.4.2 Pharmaron Beijing Business Overview
- 12.4.3 Pharmaron Beijing Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.4.4 Pharmaron Beijing Biopharmaceutical CRO Product Portfolio
- 12.4.5 Pharmaron Beijing Recent Developments
- 12.5 ICON
- 12.5.1 ICON Company Information
- 12.5.2 ICON Business Overview
- 12.5.3 ICON Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.5.4 ICON Biopharmaceutical CRO Product Portfolio
- 12.5.5 ICON Recent Developments
- 12.6 PPD
- 12.6.1 PPD Company Information
- 12.6.2 PPD Business Overview
- 12.6.3 PPD Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.6.4 PPD Biopharmaceutical CRO Product Portfolio
- 12.6.5 PPD Recent Developments
- 12.7 BioPharma Services
- 12.7.1 BioPharma Services Company Information
- 12.7.2 BioPharma Services Business Overview
- 12.7.3 BioPharma Services Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.7.4 BioPharma Services Biopharmaceutical CRO Product Portfolio
- 12.7.5 BioPharma Services Recent Developments
- 12.8 TriStar Technology Group
- 12.8.1 TriStar Technology Group Company Information
- 12.8.2 TriStar Technology Group Business Overview
- 12.8.3 TriStar Technology Group Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.8.4 TriStar Technology Group Biopharmaceutical CRO Product Portfolio
- 12.8.5 TriStar Technology Group Recent Developments
- 12.9 Fortrea
- 12.9.1 Fortrea Company Information
- 12.9.2 Fortrea Business Overview
- 12.9.3 Fortrea Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.9.4 Fortrea Biopharmaceutical CRO Product Portfolio
- 12.9.5 Fortrea Recent Developments
- 12.10 Eurofins BioPharma Services
- 12.10.1 Eurofins BioPharma Services Company Information
- 12.10.2 Eurofins BioPharma Services Business Overview
- 12.10.3 Eurofins BioPharma Services Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.10.4 Eurofins BioPharma Services Biopharmaceutical CRO Product Portfolio
- 12.10.5 Eurofins BioPharma Services Recent Developments
- 12.11 Medicilon
- 12.11.1 Medicilon Company Information
- 12.11.2 Medicilon Business Overview
- 12.11.3 Medicilon Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.11.4 Medicilon Biopharmaceutical CRO Product Portfolio
- 12.11.5 Medicilon Recent Developments
- 12.12 Asymchem
- 12.12.1 Asymchem Company Information
- 12.12.2 Asymchem Business Overview
- 12.12.3 Asymchem Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.12.4 Asymchem Biopharmaceutical CRO Product Portfolio
- 12.12.5 Asymchem Recent Developments
- 12.13 UBC
- 12.13.1 UBC Company Information
- 12.13.2 UBC Business Overview
- 12.13.3 UBC Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.13.4 UBC Biopharmaceutical CRO Product Portfolio
- 12.13.5 UBC Recent Developments
- 12.14 SanaClis
- 12.14.1 SanaClis Company Information
- 12.14.2 SanaClis Business Overview
- 12.14.3 SanaClis Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.14.4 SanaClis Biopharmaceutical CRO Product Portfolio
- 12.14.5 SanaClis Recent Developments
- 12.15 TFS HealthScience
- 12.15.1 TFS HealthScience Company Information
- 12.15.2 TFS HealthScience Business Overview
- 12.15.3 TFS HealthScience Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.15.4 TFS HealthScience Biopharmaceutical CRO Product Portfolio
- 12.15.5 TFS HealthScience Recent Developments
- 12.16 Parexel
- 12.16.1 Parexel Company Information
- 12.16.2 Parexel Business Overview
- 12.16.3 Parexel Revenue in Biopharmaceutical CRO Business (2021-2026)
- 12.16.4 Parexel Biopharmaceutical CRO Product Portfolio
- 12.16.5 Parexel Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst